RAF1 and colorectal carcinoma: To determine whether our results hold true in patient-derived material, we downregulate RAF1 in patient-derived CRC organoids (PDOs) either by stable expression of two independent doxycycline-inducible RAF1 shRNA (Colo_312 (KRASMUT/MSI; CMS1), Colo_131 (KRASMUT/MSS; CMS not determined), Colo_198 (KRASWT/MSI; CMS4), Colo_176 (KRASWT/MSS; CMS2) or by siRNA (Colo_324 (KRASWT/MSI; CMS3) (Supplementary Table 1).